Targeting CD30 in Diffuse Large B‑Cell Lymphoma: Where Does It Fit in?
Brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety.
Not provided in source content.
The activity of BV and impact on overall survival in relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) is surprising, with an increased complete response rate but short progression‑free survival, suggesting a potential bridging role before CAR‑T or other definitive options.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Diffuse Large B‑Cell Lymphoma – Global Clinical Trial Landscape (2024)
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
- Mantle‑Cell Lymphoma (MCL)
- Inhibition of autoantigen‑induced B‑cell receptor (BCR) internalization as a therapeutic strategy in diffuse large B cell lymphoma (DLBCL)
- Successful treatment of primary refractory DLBCL/HGBL - MYC/BCL2 transformed from FL using glofitamab: a case report